



## Company Announcement

Friday 1st June 2007  
Melbourne, Australia

### Clinuvel Share Purchase Plan completed

Clinuvel Pharmaceuticals Limited (ASX: **CUV**, XETRA-DAX: **UR9**) has announced the close of the Share Purchase Plan (SPP). A total of 377,570 shares were issued at A\$1.07, raising A\$404,000.

Together with the A\$26 million raised via the recent private placement to international and Australian institutions (26 April 2007), the A\$404,000 raised from the SPP has resulted in a total of A\$26.4 million in additional funding. Clinuvel's cash balance now totals approximately A\$62.5 million.

The capital raised will be used to fund the expanded program for CUV1647, the fifth indication in Photodynamic Therapy, the accelerated clinical program for Erythropoietic Protoporphyrin (EPP), global recruitment, ongoing research and development in the current bio-resorbable implant formulation, along with a potential next generation formulation.

Clinuvel would like to take this opportunity to thank all their shareholders for their ongoing support.

-END-

### For more information contact:

**Davina Gunn / Kate Liscombe**  
**Investor Relations**  
**Clinuvel Pharmaceuticals Limited**  
**Tel: +61 3 9660 4900**  
**investorrelations@clinuvel.com**

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 13 / 1 Collins Street**  
**Melbourne, Victoria 3000**  
**Australia**

**T +61 3 9660 4900**  
**F +61 3 9660 4999**

**clinuvel.com**